Capstone Investment Advisors’s Denali Therapeutics DNLI Stock Holding History

Capstone Investment Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$249K	Sell	12,963 -25,849	-67%	-$514K	﹤0.01%	1440
2025 Q4	$641K	Buy	+38,812	New	+$655K	﹤0.01%	1049
2024 Q2	–	Sell	-19,741	Closed	-$405K	–	2172
2024 Q1	$405K	Sell	19,741 -3,148	-14%	-$59.2K	﹤0.01%	1672
2023 Q4	$491K	Sell	22,889 -14,678	-39%	-$291K	﹤0.01%	1348
2023 Q3	$775K	Buy	+37,567	New	+$953K	﹤0.01%	1084

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capstone Investment Advisors's DNLI Position: Q1 2026 in Review

Capstone Investment Advisors reduced its Denali Therapeutics (DNLI) stake by 67% in Q1 2026, selling an estimated $514K and leaving 12,963 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #1440.

Capstone Investment Advisors first reported a position in DNLI in Q3 2023 and has held it in 5 quarters since. The position peaked at $775K in Q3 2023. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Capstone Investment Advisors held 12,963 shares of Denali Therapeutics worth $249K as of Q1 2026.
Capstone Investment Advisors sold 25,849 Denali Therapeutics shares in Q1 2026, an estimated $514K.
Denali Therapeutics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1440 holding.
Capstone Investment Advisors first reported a position in Denali Therapeutics in Q3 2023 and has held it in 5 quarters since.
Capstone Investment Advisors's Denali Therapeutics position peaked at $775K in Q3 2023.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.